IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study

By sjmartinez • September 28, 2023

Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, Ikeda M, Tsuchiya K, Aoki KI, Jia J, Lencioni R. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study. Liver Cancer. 2022 Nov 28;12(3):238-250. doi: 10.1159/000528272. PMID: 37767068; PMCID: PMC10521324.

Tags: Atezolizumab, Barcelona Clinic Liver Cancer stage B, Bevacizumab, Hematology/Oncology, Publications, unresectable

Related Posts

Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results

Hochman MJ, Ruppert AS, Huang Y, Mims A, Borate U, Swords R, Traer E, Baer MR, Duong VH, Stock W, Odenike T, Patel P, Madanat[...]

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

Fakih M, Gill S, Sampat K, Chan DL, Fisher G, Cruz-Correa M, Lenz HJ, Garcia-Alfonso P, Forget F, Lonardi S, Krauss J, Chen E, Cubillo[...]

Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease

Prueksapraopong C, Fernandes A, Campo Fernandez B, Roy S, Hollis RP, Habtemariam B, Pellin D, Ceoldo G, Lin TY, Dang TT, Cornetta K, Romero Z,[...]